Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1994 Nov;57(Suppl):46–49. doi: 10.1136/jnnp.57.suppl.46

Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy.

J M Leger 1, A B Younes-Chennoufi 1, B Chassande 1, G Davila 1, P Bouche 1, N Baumann 1, P Brunet 1
PMCID: PMC1016725  PMID: 7964853

Abstract

Intravenous human immune globulin (IVIg) has been proposed for the treatment of various peripheral neuropathies that are considered to be immunemediated. The results are reported of an open trial conducted in multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. Six cases with multifocal motor neuropathy, selected on clinical and electrophysiological criteria (four of six patients also had significantly high anti-GM1 titres), received IVIg monthly, at doses varying from 1.6 to 2.5 mg/kg, over three to 13 months. The initial response to treatment was dramatic in 3/6 cases (with improvement of at least two grades on the MRC scale in the five more severely affected muscles). The final evaluation showed a good result in 4/6 cases, but the conduction blocks were not significantly reduced. In 13 other cases with polyneuropathy associated with IgM monoclonal gammopathy of unknown significance, IVIg was of benefit, with improvement of at least one grade on the Prineas score, in 4/7 cases previously treated with immunosuppression and 2/3 cases not treated before IVIg. In the last group of four patients with polyneuropathy and IgG monoclonal gammopathy, IVIg was followed by clinical improvement in the two cases with a chronic demyelinating polyneuropathy.

Full text

PDF
46

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auer R. N., Bell R. B., Lee M. A. Neuropathy with onion bulb formations and pure motor manifestations. Can J Neurol Sci. 1989 May;16(2):194–197. doi: 10.1017/s0317167100028894. [DOI] [PubMed] [Google Scholar]
  2. Azulay J. P., Blin O., Pouget J., Boucraut J., Billé-Turc F., Carles G., Serratrice G. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology. 1994 Mar;44(3 Pt 1):429–432. doi: 10.1212/wnl.44.3_part_1.429. [DOI] [PubMed] [Google Scholar]
  3. Ben Younes-Chennoufi A., Meininger V., Léger J. M., Bouche P., Jauberteau M. O., Baumann N. Antiganglioside antibodies in motor-neuron diseases and peripheral neuropathies: study by ELISA technique and immunodetection on thin-layer chromatography. Neurochem Int. 1992 Apr;20(3):353–357. doi: 10.1016/0197-0186(92)90049-w. [DOI] [PubMed] [Google Scholar]
  4. Ben Younes-Chennoufi A., Meininger V., Léger J. M., Bouche P., Jauberteau M. O., Baumann N. Antiganglioside antibodies in motor-neuron diseases and peripheral neuropathies: study by ELISA technique and immunodetection on thin-layer chromatography. Neurochem Int. 1992 Apr;20(3):353–357. doi: 10.1016/0197-0186(92)90049-w. [DOI] [PubMed] [Google Scholar]
  5. Braun P. E., Frail D. E., Latov N. Myelin-associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem. 1982 Nov;39(5):1261–1265. doi: 10.1111/j.1471-4159.1982.tb12563.x. [DOI] [PubMed] [Google Scholar]
  6. Cook D., Dalakas M., Galdi A., Biondi D., Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology. 1990 Feb;40(2):212–214. doi: 10.1212/wnl.40.2.212. [DOI] [PubMed] [Google Scholar]
  7. Cornblath D. R., Chaudhry V., Griffin J. W. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol. 1991 Jul;30(1):104–106. doi: 10.1002/ana.410300119. [DOI] [PubMed] [Google Scholar]
  8. Dalakas M. C., Flaum M. A., Rick M., Engel W. K., Gralnick H. R. Treatment of polyneuropathy in Waldenström's macroglobulinemia: role of paraproteinemia and immunologic studies. Neurology. 1983 Nov;33(11):1406–1410. doi: 10.1212/wnl.33.11.1406. [DOI] [PubMed] [Google Scholar]
  9. Dyck P. J., Low P. A., Windebank A. J., Jaradeh S. S., Gosselin S., Bourque P., Smith B. E., Kratz K. M., Karnes J. L., Evans B. A. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med. 1991 Nov 21;325(21):1482–1486. doi: 10.1056/NEJM199111213252105. [DOI] [PubMed] [Google Scholar]
  10. Feldman E. L., Bromberg M. B., Albers J. W., Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol. 1991 Sep;30(3):397–401. doi: 10.1002/ana.410300312. [DOI] [PubMed] [Google Scholar]
  11. Fineman S. M., McKendall R. R. Plasma exchange: a treatment for neuropathy associated with IgG-kappa gammopathy. J Neurol. 1990 Apr;237(2):85–87. doi: 10.1007/BF00314667. [DOI] [PubMed] [Google Scholar]
  12. GARCIN R., MALLARME J., RONDOT P. Forme névritique de la macroglobulinémie de Waldenström. Bull Mem Soc Med Hop Paris. 1958 Jul 4;74(24-25):562–573. [PubMed] [Google Scholar]
  13. Hoang-Xuan K., Léger J. M., Ben Younes-Chennoufi A., Saidi H., Bouche P., Baumann N., Brunet P. Traitement des neuropathies dysimmunitaires par immunoglobulines polyvalentes intraveineuses. Etude ouverte de 16 cas. Rev Neurol (Paris) 1993;149(6-7):385–392. [PubMed] [Google Scholar]
  14. Jauberteau M. O., Henin D., Bouche P., Vallat J. M., Dumas M., Dellagi S., Leger J. M., Harpin M. L., Ratinahirana H., Chaunu M. P. Etude des anticorps antiglycolipides au cours des dysglobulinémies monoclonales à IgM associées à une neuropathie périphérique. Rev Neurol (Paris) 1988;144(8-9):474–480. [PubMed] [Google Scholar]
  15. Kelly J. J., Jr, Kyle R. A., Miles J. M., Dyck P. J. Osteosclerotic myeloma and peripheral neuropathy. Neurology. 1983 Feb;33(2):202–210. doi: 10.1212/wnl.33.2.202. [DOI] [PubMed] [Google Scholar]
  16. Krarup C., Stewart J. D., Sumner A. J., Pestronk A., Lipton S. A. A syndrome of asymmetric limb weakness with motor conduction block. Neurology. 1990 Jan;40(1):118–127. doi: 10.1212/wnl.40.1.118. [DOI] [PubMed] [Google Scholar]
  17. Leger J. M., Vaunaize J. Polyneuropathy associated with IgM monoclonal gammopathy: a review. Clinical, electrophysiological and pathological features. Nouv Rev Fr Hematol. 1990;32(5):303–306. [PubMed] [Google Scholar]
  18. Lewis R. A., Sumner A. J., Brown M. J., Asbury A. K. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982 Sep;32(9):958–964. doi: 10.1212/wnl.32.9.958. [DOI] [PubMed] [Google Scholar]
  19. Meier C. Polyneuropathy in paraproteinaemia. J Neurol. 1985;232(4):204–214. doi: 10.1007/BF00313781. [DOI] [PubMed] [Google Scholar]
  20. Nobile-Orazio E., Baldini L., Barbieri S., Marmiroli P., Spagnol G., Francomano E., Scarlato G. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol. 1988 Jul;24(1):93–97. doi: 10.1002/ana.410240118. [DOI] [PubMed] [Google Scholar]
  21. Nobile-Orazio E., Meucci N., Barbieri S., Carpo M., Scarlato G. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology. 1993 Mar;43(3 Pt 1):537–544. doi: 10.1212/wnl.43.3_part_1.537. [DOI] [PubMed] [Google Scholar]
  22. Parry G. J., Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve. 1988 Feb;11(2):103–107. doi: 10.1002/mus.880110203. [DOI] [PubMed] [Google Scholar]
  23. Pestronk A., Cornblath D. R., Ilyas A. A., Baba H., Quarles R. H., Griffin J. W., Alderson K., Adams R. N. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988 Jul;24(1):73–78. doi: 10.1002/ana.410240113. [DOI] [PubMed] [Google Scholar]
  24. Roth G., Rohr J., Magistris M. R., Ochsner F. Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia. Eur Neurol. 1986;25(6):416–423. doi: 10.1159/000116045. [DOI] [PubMed] [Google Scholar]
  25. Smith I. S., Kahn S. N., Lacey B. W., King R. H., Eames R. A., Whybrew D. J., Thomas P. K. Chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. Brain. 1983 Mar;106(Pt 1):169–195. doi: 10.1093/brain/106.1.169. [DOI] [PubMed] [Google Scholar]
  26. Vermeulen M., van Doorn P. A., Brand A., Strengers P. F., Jennekens F. G., Busch H. F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):36–39. doi: 10.1136/jnnp.56.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Younes-Chennoufi A. B., Léger J. M., Hauw J. J., Preud'homme J. L., Bouche P., Aucouturier P., Ratinahirana H., Lubetzki C., Lyon-Caen O., Baumann N. Ganglioside GD1b is the target antigen for a biclonal IgM in a case of sensory-motor axonal polyneuropathy: involvement of N-acetylneuraminic acid in the epitope. Ann Neurol. 1992 Jul;32(1):18–23. doi: 10.1002/ana.410320105. [DOI] [PubMed] [Google Scholar]
  28. van Doorn P. A., Brand A., Strengers P. F., Meulstee J., Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990 Feb;40(2):209–212. doi: 10.1212/wnl.40.2.209. [DOI] [PubMed] [Google Scholar]
  29. van Doorn P. A., Vermeulen M., Brand A., Mulder P. G., Busch H. F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol. 1991 Feb;48(2):217–220. doi: 10.1001/archneur.1991.00530140113024. [DOI] [PubMed] [Google Scholar]
  30. van der Meché F. G., Schmitz P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992 Apr 23;326(17):1123–1129. doi: 10.1056/NEJM199204233261705. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES